Posters –
Infectious diseases & Vaccines
NAME OF THE PROJECT
NAME OF THE MAIN CONTACT
ORGANISATION NAME
Technology
Customers / Target market
FluVac: Optimization of cell-culture-based production of influenza vaccine using small
eliciting molecules
Daphné Thomas - daphne.thomas@pulsalys.fr - +33 (0)4.26.23.56.78
PULSALYS
The laboratory has developed a process to optimize the production rate of Influenza
vaccine strains, to be used in cell-culture-based systems of production. This process is
based on the use of small molecules related to proviral activity, as a booster for vaccine A
and B strains production within animal cells. The gain of production reaches +88% over
several replication cycles in cell culture.
With the new four-strain flu vaccines coming into the market, this technology provides an
efficient tool to optimize manufacturing costs and rate of next-generation vaccines.
Human & Veterinary vaccine industry : vaccine manufacturers, big pharma …
Industry and competitors
Sanofi-pasteur, Valneva, Abbott, MedImmune, Takeda, Baxter, ViroNovative, Crucell,
Pflizer, Merck, GSK…
Fort Dodge, CEVA Santé Animale, Bayer Animal Health, Merial, Pfizer Animal Health,
Boehringer Ingelheim, Merck Animal Health…
Financing need / Commercial
opportunity
We are looking for a partnership with vaccine manufacturers or subcontractors to
collaborate on proprietary cell lines, for further licensing.
IP – Patent situation
Future steps / Milestones
Patent pending in EP, US, CA, CN, JP.
Priority date: November 5th, 2010 (FR1059132)
Collaboration with proprietary cell-lines
Further reading
N/A
Contact person
Daphné Thomas, Tech Transfer Officer – Health & Life Sciences, SATT Pulsalys,
daphne.thomas@pulsalys.fr - +33 (0)4.26.23.56.78